Le Lézard2m
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
AbbVie today announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in adult patients.
Why 'game changing' item is a must-have for parents travelling to Europe for 2025 (and it's currently on sale): 'Don't go without it'
If you're planning a European holiday with the family, there's one non-negotiable item you need to make the journey as stress ...